ASCO GI 2025 | CD47 Blockade Combination Therapy Shows Anti-Tumor Potential in Previously Treated HER2-Positive Gastric Cancer

ASCO GI 2025 | CD47 Blockade Combination Therapy Shows Anti-Tumor Potential in Previously Treated HER2-Positive Gastric Cancer

2025.02.24
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients with HER2-positive gastric and esophageal cancer who had previously received anti-HER2 therapy but experienced disease progression. At the conference, a reporter from Oncology Frontier had the opportunity to conduct an exclusive interview with Dr. Kohei Shitara from the National Cancer Center Hospital in Japan regarding this study. The following is a summary of the discussion.
ASCO GI 2025 | Dr. Ying Yuan: BBCAPX Regimen as a Potential Immunotherapy Breakthrough for RAS-Mutant MSS mCRC with Liver Metastases

ASCO GI 2025 | Dr. Ying Yuan: BBCAPX Regimen as a Potential Immunotherapy Breakthrough for RAS-Mutant MSS mCRC with Liver Metastases

2025.02.24
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) commenced in San Francisco on January 23, 2025. During the conference, Dr. Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine presented the latest survival data and subgroup analysis from the BBCAPX study. Oncology Frontier had the privilege of discussing the updated findings with Dr. Ying Yuan. This article summarizes the key insights from the study to provide valuable updates for clinicians and researchers.
Dr. Hui Wei: Advances in Targeted Therapy for FLT3-Mutated AML | 2025 CSCO Hematologic Oncology Conference

Dr. Hui Wei: Advances in Targeted Therapy for FLT3-Mutated AML | 2025 CSCO Hematologic Oncology Conference

2025.02.23
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with FLT3 mutations among the most common molecular abnormalities, significantly impacting patient prognosis. As our understanding of AML pathogenesis deepens, novel targeted therapies, including FLT3 inhibitors, have emerged, offering new hope for patients with FLT3-mutated AML. From January 17 to 19, 2025, the "CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting & 2025 CSCO Hematologic Oncology Conference" was held in Haikou, China. During the event, Hematology Frontier had the privilege of interviewing Dr. Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. He shared insights into the prevalence of FLT3 mutations in AML, recent advancements in targeted therapy, and future optimization strategies.
Integrons and the Spread of Beta-Lactam Resistance

Integrons and the Spread of Beta-Lactam Resistance

2025.02.22
New insights highlight integrons as key players in the dissemination of beta-lactamase (BL) genes, driving resistance to carbapenems and other beta-lactams. A review of 1981 integrons from clinical and environmental settings shows their role in capturing and spreading BL genes across multiple bacterial genera, with Pseudomonas aeruginosa as the most frequent host.
Brain Abscess Outcomes in the Modern Imaging Era

Brain Abscess Outcomes in the Modern Imaging Era

2025.02.22
A new meta-analysis in Journal of Infection examines how CT and MRI have influenced brain abscess diagnosis and treatment, analyzing data from 21,840 patients between 1980 and 2022. The findings show that brain abscess remains more common in men, with Streptococcus spp. (32%), Staphylococcus spp. (14%), and Gram-negative bacteria (9%) as the leading pathogens. Key risk factors include otitis/mastoiditis (27%), immunocompromise (19%), and sinusitis (16%).